Company intelligence / Profile preview

Synageva BioPharma

Lexington, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Synageva was a rare disease-focused biotech company with multiple enzyme replacement therapy programs in development. The company's lead program, Kanuma (sebelipase alfa), was under Priority Review with the FDA and accelerated assessment with the EMA as of mid-2015, with regulatory decisions expected in the second half of 2015. The company's second program, SBC-103 for MPS IIIB, was in Phase 1/2 trials and had received Fast Track designation from the FDA in January 2015.

Therapeutic areas: Rare Diseases
Modalities: Enzyme replacement therapyRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Synageva BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synageva BioPharma.

Explore the full profile